Synopsis of the Global Bronchitis Market
Bronchitis is nothing but the inflammation of the lining of bronchial tubes of the lungs. It is of two types, namely, acute and chronic bronchitis. Acute bronchitis, also known as a chest cold, is found to be very common and develops from a cold or other respiratory infection. On the other hand, chronic bronchitis is a severe condition which is characterized by constant irritation or inflammation of the lining of bronchial tubes. It is included in the Chronic Obstructive Pulmonary Disease (COPD). Shortness of breath, cough, slight fever and chills, production of mucus, fatigue, and chest discomfort are major symptoms of bronchitis. It can be diagnosed through various tests such as chest X-ray, sputum tests, and pulmonary function test.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5735
The global bronchitis market is mainly driven by the increasing prevalence of lung diseases such as bronchitis, asthma, COPD, availability of drugs for the treatment, and drugs. Additionally, increasing number of diagnostic services for various chronic diseases and the use of technologically advanced devices for diagnosis also drive the growth of the market. Other factors supporting the market growth are an addiction to smoking and changing lifestyle. However, fierce competition among the existing market players restrains the growth of the market.
The global bronchitis market is expected to grow at a CAGR of 5.3% during the forecast period.
Major Players in the Bronchitis Market: Some of the key players in the global market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others. Regional Analysis The market for bronchitis is found to be increasing in Americas, which is driven by growing awareness about risk factors of COPD and bronchitis and rising emphasis on healthy lifestyle and prevention of lung diseases. In the U.S., the bronchitis market is fueled by the presence of major market players and extensive use of diagnostic services. The rapid growth in diagnostic and treatment services also accelerates the growth of the market. In Europe, the major factors accelerating the market are extensive research and development in the field of respiratory diseases and increase in the number of players in the market manufacturing drugs for the treatment of diseases. Germany is the largest contributor to the market growth. In Asia Pacific, the market is driven by the rising prevalence of chronic diseases including respiratory diseases and increasing environmental pollution. In the Middle East and Africa, rising awareness about lung diseases among adults and development of the healthcare sector drive the growth of the market. Segmentation The global bronchitis market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into acute bronchitis and chronic bronchitis. On the basis of diagnosis, the market is segmented into chest X-ray, sputum tests, and pulmonary function tests. On the basis of treatment, the market is segmented into drugs and oxygen therapy. Drugs is further segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, research institutes, and others. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bronchitis-market-5758
コメント